rVWF IN PROPHYLAXIS

Inclusion Criteria:

1. Participant has a documented diagnosis of severe von Willebrand disease (VWD) (baseline Von Willebrand factor: Ristocetin cofactor activity (VWF:RCo) less than (<) 20 International Units/Deciliter [IU/dL]) with a history of requiring substitutiontherapy with von Willebrand factor concentrate to control bleeding
2. Type 1 (VWF:RCo <20 IU/dL) or,
3. Type 2A (as verified by multimer pattern), Type 2B (as diagnosed by genotype),Type 2M or,
4. Type 3 (Von Willebrand factor antigen (VWF:Ag) less than or equal to [< or =] 3IU/dL).
5. Diagnosis is confirmed by genetic testing and multimer analysis, documented in patienthistory or at screening.
6. For on-demand patient group, participant currently receiving on-demand treatment forwhom prophylactic treatment is recommended by the investigator.
7. For Plasma derived von Willebrand factor (pdVWF) product switch patient group,participant has been receiving prophylactic treatment of pdVWF products for no lessthan 12 months prior to screening.
8. For on-demand patient group, participant has greater than or equal to (>or=) 3documented spontaneous bleeds (not including menorrhagia) requiring von Willebrandfactor (VWF) treatment during the past 12 months.
9. Availability of records to reliably evaluate type, frequency and treatment of bleedingepisodes during at least 12 months preceding enrollment. Up to 24 months retrospectivedata should be collected if available. Availability of dosing and factor consumptionduring 12 months (up to 24 months) of treatment prior to enrollment is required forpdVWF switch participants and is desired (but not a requirement) for on-demandparticipants.
10. Participant is > or = 18 years old at the time of screening and has a body mass index > or = 15 but <40 kilogram per meter square (kg/m^2).
11. If female of childbearing potential, participant presents with a negative blood/urinepregnancy test at screening and agrees to employ adequate birth control measures forthe duration of the study.
12. Participant is willing and able to comply with the requirements of the protocol.

Exclusion Criteria:

1. The participant has been diagnosed with Type 2N Von Willebrand disease (VWD), pseudoVWD, or another hereditary or acquired coagulation disorder other than VWD (egqualitative and quantitative platelet disorders or prothrombin time [PT]/internationalnormalized ratio [INR] greater than [>]1.4).
2. The participant is currently receiving prophylactic treatment with more than 5infusions per week.
3. The participant is currently receiving prophylactic treatment with a weekly doseexceeding 240 IU/kg.
4. The participant has a history or presence of a VWF inhibitor at screening.
5. The participant has a history or presence of a Factor VIII (FVIII) inhibitor with atiter ≥0.4 Bethesda units (BU) (by Nijmegen modified Bethesda assay) or > or = 0.6Bethesda Unit (BU) (by Bethesda assay).
6. The participant has a known hypersensitivity to any of the components of the studydrugs, such as to mouse or hamster proteins.
7. The participant has a medical history of immunological disorders, excluding seasonalallergic rhinitis/conjunctivitis, mild asthma, food allergies or animal allergies.
8. The participant has a medical history of a thromboembolic event.
9. The participant is human immunodeficiency virus (HIV) positive with an absolute HelperT cell (CD4) count <200/ cubic millimeter (mm^3).
10. The participant has been diagnosed with significant liver disease per investigator'smedical assessment of the participant's current condition or medical history or asevidenced by any of the following: serum alanine aminotransferase (ALT) greater than 5times the upper limit of normal; hypoalbuminemia; portal vein hypertension (e.g.,presence of otherwise unexplained splenomegaly, history of esophageal varices).
11. The participant has been diagnosed with renal disease, with a serum creatinine (CR)level > or = 2.5 milligram per deciliter (mg/dL).
12. The participant has a platelet count <100,000/ milliliter (mL) at screening.
13. The participant has been treated with an immunomodulatory drug, excluding topicaltreatment (e.g., ointments, nasal sprays), within 30 days prior to signing theinformed consent.
14. The participant is pregnant or lactating at the time of enrollment.
15. Patient has cervical or uterine conditions causing menorrhagia or metrorrhagia (including infection, dysplasia).
16. The participant has participated in another clinical study involving anotherInvestigational product (IP) or investigational device within 30 days prior toenrollment or is scheduled to participate in another clinical study involving an IP orinvestigational device during the course of this study.
17. The participant has a progressive fatal disease and/or life expectancy of less than 15months.
18. The participant is scheduled for a surgical intervention.
19. The participant is identified by the investigator as being unable or unwilling tocooperate with study procedures.
20. The participant has a mental condition rendering him/her unable to understand thenature, scope and possible consequences of the study and/or evidence of anuncooperative attitude.
21. The participant is in prison or compulsory detention by regulatory and/or juridicalorder.
22. The participant is member of the study team or in a dependent relationship with one ofthe study team members which includes close relatives (i.e., children, partner/spouse,siblings and parents) as well as employees.